Literature DB >> 10928052

Role of metastatic potential in the adhesion of human breast cancer cells to endothelial monolayers.

M A Moss1, S Zimmer, K W Anderson.   

Abstract

To gain further insight into the process of metastasis, adhesion to endothelial monolayers was compared for a nonmetastatic and a highly metastatic human breast cancer cell line. The parallel plate flow chamber was employed to quantify adhesion using an attachment assay. This assay was carried out at several physiological shear stresses both with and without endothelial TNF-alpha stimulation. At a venular shear stress of 1 dyne cm-2, the nonmetastatic cell line was more adhesive to stimulated endothelial monolayers, while no differences could be noted for resting monolayers. At a lower shear stress of 0.25 dynes cm-2, the highly metastatic cell line was more adhesive to stimulated endothelial monolayers, while the nonmetastatic cell line was more adhesive to resting monolayers. Thus, metastatic potential correlated with attachment only at low shear stresses and following endothelial stimulation. These results emphasize the importance of studying cancer cell adhesion under multiple physiological flow conditions. Furthermore, these results indicate that adhesion of these two cell lines may be controlled by two different mechanisms. Antibody blocking experiments of adhesion molecules on the endothelial cells confirmed that adhesion of the nonmetastatic cell line was mediated by E-selectin expressed on the endothelial cells and adhesion of the highly metastatic cell line was mediated by both E-selectin and VCAM-1 expressed on the endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928052

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Targeting selectins and selectin ligands in inflammation and cancer.

Authors:  Steven R Barthel; Jacyln D Gavino; Leyla Descheny; Charles J Dimitroff
Journal:  Expert Opin Ther Targets       Date:  2007-11       Impact factor: 6.902

2.  In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells.

Authors:  Gunjan Gakhar; Neil H Bander; David M Nanus
Journal:  J Vis Exp       Date:  2014-05-15       Impact factor: 1.355

3.  A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.

Authors:  Joseph Baar; Paula Silverman; Janice Lyons; Pingfu Fu; Fadi Abdul-Karim; Nicholas Ziats; Jay Wasman; Paul Hartman; John Jesberger; Leda Dumadag; Erin Hohler; Rosemary Leeming; Robert Shenk; Helen Chen; Keith McCrae; Afshin Dowlati; Scot C Remick; Beth Overmoyer
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

4.  Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells.

Authors:  Venktesh S Shirure; Nathan M Reynolds; Monica M Burdick
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

5.  ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.

Authors:  Roberto Coppo; Francesca Orso; Federico Virga; Alberto Dalmasso; Desirée Baruffaldi; Lei Nie; Fabiana Clapero; Daniela Dettori; Lorena Quirico; Elena Grassi; Paola Defilippi; Paolo Provero; Donatella Valdembri; Guido Serini; Mehran M Sadeghi; Massimiliano Mazzone; Daniela Taverna
Journal:  Cancer Lett       Date:  2021-04-13       Impact factor: 9.756

6.  CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration.

Authors:  Ke Zen; Dan-Qing Liu; Ya-Lan Guo; Chen Wang; Jun Shan; Ming Fang; Chen-Yu Zhang; Yuan Liu
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

7.  Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma.

Authors:  Leticia Oliveira-Ferrer; Karin Milde-Langosch; Kathrin Eylmann; Maila Rossberg; Volkmar Müller; Barbara Schmalfeldt; Isabell Witzel; Jasmin Wellbrock; Walter Fiedler
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.